Moberg Begins Recruiting Patients for Phase III Dermatitis Trial
Posted on: Monday, 25 February 2008, 12:01 CST
Moberg Derma has started recruiting patients for a clinical Phase III trial of the K301 product candidate to treat seborrheic dermatitis of the scalp.
The company plans to include 180 patients in the study at around 20 clinics in Sweden. The results from the trial are expected in the second half of 2008.
Peter Wolpert, CEO of Moberg Derma, said: "We recently received the approval from the Swedish Medical Products Agency and Ethical Committee and will now initiate our second Phase III study. If the promising data from our previous Phase II trial can be reproduced in this larger study, we will be able to offer patients a novel and efficacious topical treatment for seborrheic dermatitis of the scalp."
Source: Datamonitor
Related Articles
- InteKrin Therapeutics Announces Enrollment Completion of 360 Patient, 24 week Phase 2b Study
- Glenmark Expects Launch of Crofelemer in ROW Countries(Developing Economies) by 2010 - Potential First-in-Class for HIV-Associated Diarrhea: Molecule Currently in Phase 3 Trials, Granted Fast Track Designation by US-FDA
- Micromet Presents Updated Data on the Phase 1 Trial Studying Blinatumomab (MT103/MEDI-538) in Patients with Advanced Non-Hodgkin's Lymphoma
- Metabolex Completes Patient Enrollment in Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
- Celsion Commences Global Phase III Study for Primary Liver Cancer
- Novacea Initiates Phase 2 Trial of Asentar in Advanced Pancreatic Cancer
- Theravance Announces Positive Results From Phase 2 Clinical Study in Chronic Constipation With Investigational Compound TD-5108
- Results of 340 Patient Phase III Study Using BSD Medical's Cancer Therapy Systems to Be Announced at ASCO Annual Meeting
- Linaclotide Shown to Improve Symptoms of Chronic Constipation in Phase 2a Study
- Synthetic Blood Updates Traumatic Brain Injury Trial Enrollment; Six of Eight Patients Treated in Phase II Study
 |
 |
User Comments (0)
RSS Feeds